Business
Savara Announces the U.S. Food and Drug Administration (FDA) Filed the MOLBREEVI* Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
LANGHORNE, Pa., February 20, 2026--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical-stage biopharmaceutical company focused on rare respiratory diseases, announced the FDA has filed for review the BLA for MOLBREEVI as a therapy to treat patients with autoimmune PAP. The FDA granted Priority Review with a PDUFA action date of August 22, 2026.
About this update from Savara, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/7d4e4be0e904898ba55e6e3607866600"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/5aVePH.W8HQiAnmQ1SIpyA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/7d4e4be0e904898ba55e6e3607866600","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/_pQu.Eq9WoSF76gpT_Carw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/7d4e4be0e904898ba55e6e3607866600","width":1024,"height":512}},"lazy":false},{"type":"text","content":"-- Priority Review Granted, Prescription Drug User Fee Act (PDUFA) Target Action Date Set for August 22, 2026 --","length":112,"tagName":"p","attribs":{}},{"type":"text","content":"-- Company Plans to Submit the MOLBREEVI Marketing Authorization Applications (MAAs) for Autoimmune PAP to the European Medicines Agency (EMA) and the Medicines and Healthcare Products Regulatory Agency (MHRA) By the End of Q1 2026 --","length":234,"tagName":"p","attribs":{}},{"type":"text","content":"-- MOLBREEVI Has the Potential to Be the First and Only Approved Therapy for Autoimmune PAP in the U.S. and Europe --","length":117,"tagName":"p","attribs":{}},{"type":"text","content":"LANGHORNE, Pa., February 20, 2026--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical-stage biopharmaceutical company focused on rare respiratory diseases, announced the FDA has filed for review the BLA for MOLBREEVI as a therapy to treat patients with autoimmune PAP. The FDA granted Priority Review with a PDUFA action date of August 22, 2026.","length":364,"tagName":"p"},{"type":"text","content":""The FDA’s filing of the BLA marks another significant milestone for Savara and the autoimmune PAP community and brings us one step closer to a potential approval in the U.S. in August of this year," said Matt Pauls, Chair and Chief Executive Officer, Savara. "We believe the considerable body of data in the application demonstrates MOLBREEVI improves pulmonary gas transfer, quality of life, and the clinical symptoms associated with this rare and debilitating lung disease. We are grateful to the FDA for the construct...